Clinical trials: Peritoneal Damage
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Traumatic Injury
Direct Peritoneal Resuscitation Effects in the Damage Control Patient
The purpose of this study is to find if direct peritoneal resuscitation helps blood flow through important organs in a person's body after they have had a traumatic injury with massive blood loss.
- Trial name
- NCT01771055
- Testing
- Galactose, Standard surgical methods
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Louisville
Ovarian Cancer, Primary Peritoneal Cancer
Phase II ABT-888 With Cyclophosphamide
Background: The experimental cancer treatment drug ABT-888 (Veliparib) works by preventing deoxyribonucleic acid (DNA) repair in tumor cells.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer
- Trial name
- NCT01306032
- Testing
- ABT-888, Cyclophosphamide
- Where
- 10 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Damage
Peritoneal Damage in Laparoscopic Surgery
The investigators hypothesized that applying a low intraperitoneal pressure pneumoperitoneum (≤ 8mmHg) during laparoscopic cholecystectomy, the adverse impact on the surgical peritoneal environment (measured as gene expression of…
- Trial name
- NCT03020641
- Testing
- Low pressure pneumoperitoneum, standard pneumoperitoneum pressure
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.